Positron emission tomography and computed tomography activation protein inhibitors improves tumor detection pancreatic cancer

European Journal of Nuclear Medicine and Molecular Imaging 49, 1322-1337

DOI: 10.1007/s00259-021-05576-w

Citation Report

#	Article	IF	CITATIONS
1	Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2844-2868.	3.3	43
2	Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics, 2022, 12, 1557-1569.	4.6	61
3	Non-oncologic incidental uptake on FAPI PET/CT imaging. British Journal of Radiology, 2023, 96, .	1.0	25
4	Serous Cystadenoma of the Pancreas Showing Increased Uptake on 68Ga-FAPI PET/CT. Clinical Nuclear Medicine, 0, Publish Ahead of Print, .	0.7	1
5	The application of FAPI-targeted theranostics in pancreatic cancer: a narrative review. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0
6	From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ca]Ga-DATA5m.SA.FAPi. Pharmaceuticals, 2022, 15, 1000.	1.7	10
7	FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics, 2022, 12, 1958.	1.3	14
8	Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy. Pharmaceuticals, 2022, 15, 958.	1.7	5
9	PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using ⁶⁸ Ga-FAP-2286: Comparison with ¹⁸ F-FDG and ⁶⁸ Ga-FAPI-46 in a Single-Center, Prospective Study. Journal of Nuclear Medicine, 2023, 64, 386-394.	2.8	24
10	Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74. Cancers, 2022, 14, 5301.	1.7	7
11	Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors. Clinical Nuclear Medicine, 2023, 48, 35-42.	0.7	17
12	Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications. European Journal of Radiology Open, 2022, 9, 100455.	0.7	1
13	Current research topics in FAPI theranostics: a bibliometric analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1014-1027.	3.3	16
14	FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Radiology, 2023, 306, .	3.6	46
15	Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers. Clinical Nuclear Medicine, 2023, 48, 132-142.	0.7	3
16	Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 3863.	1.8	6
17	Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer. PET Clinics, 2023, , .	1.5	0
18	The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies. Cancers, 2023, 15, 1193.	1.7	5

#	Article	IF	CITATIONS
19	Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	2
20	FAPI-avid nonmalignant PET/CT findings: An expedited systematic review. Seminars in Nuclear Medicine, 2023, 53, 694-705.	2.5	17
21	The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG. European Radiology, 2023, 33, 5007-5016.	2.3	7
31	From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment. Cellular Oncology (Dordrecht), 0, , .	2.1	1
36	Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects. Annals of Nuclear Medicine, 0, , .	1.2	0